Solin L J, McCormick B, Recht A, Haffty B G, Taylor M E, Kuske R R, Bornstein B A, McNeese M, Schultz D J, Fowble B L, Barrett W, Yeh I T, Kurtz J M, Amalric R, Fourquet A
Department of Radiation Oncology, Hospital of the University of Pennsylvania School of Medicine, Philadephia 19104, USA.
Cancer J Sci Am. 1996 May-Jun;2(3):158-65.
Ductal carcinoma in situ (DCIS) is increasingly detected as a nonpalpable lesion on mammographic screening performed for the early detection of breast cancer. Because of the growing incidence of mammographically detected DCIS, the present study was undertaken to determine the outcome of treatment of nonpalpable, mammographically detected intraductal carcinoma of the breast using breast-conserving surgery and definitive breast irradiation.
An analysis was performed of 110 women who presented with unilateral, nonpalpable, mammographically detected intraductal carcinoma of the breast and who were treated with breast-conserving surgery and definitive breast irradiation at 10 institutions in Europe and the United States. In all patients, complete gross excision of the primary tumor was performed, and breast irradiation was delivered with definitive intent. When performed, pathologic axillary lymph node staging was node negative (n=29). The median follow-up time was 9.3 years.
The 10-year actuarial overall survival rate was 93%, and the 10-year actuarial cause-specific survival rate was 96%. The 10-year actuarial rate of freedom from distant metastases was 96%. There were 15 local recurrences in the treated breast. The actuarial rate of local failure was 7% at 5 years and 14% at 10 years. The histology of the local recurrence was intraductal carcinoma in 9 cases and invasive ductal carcinoma (with or without associated intraductal carcinoma) in 6 cases. The median time to local recurrence was 5.0 years (mean, 5.4; range, 2.1-15.2). With a median follow-up time of 4.4 years after salvage treatment, 14 of the 15 patients with local recurrence were alive without evidence of disease at the time of last follow-up examination. The crude incidence of local recurrence was 7% (3/42) when the final pathology margin of tumor excision was negative, 29% (5/17) when the margin was close or positive, and 14% (7/51) when the margin was unknown. There was no difference in the rate of local recurrence based on pathologic characteristics of the primary tumor.
Results from the present study demonstrate high rates of overall survival, cause-specific survival, and freedom from distant metastases at 10 years following the treatment of nonpalpable, mammographically detected DCIS of the breast using breast-conserving surgery and definitive breast irradiation. Local recurrences within the treated breast were detected early and were treated with salvage for cure. These results support the initial treatment of nonpalpable, mammographically detected DCIS of the breast using breast-conserving surgery and definitive breast irradiation. Improvements in patient selection have the potential to reduce the risk of local recurrence.
导管原位癌(DCIS)在为早期发现乳腺癌而进行的乳腺钼靶筛查中越来越多地被检测为不可触及的病变。由于乳腺钼靶检测到的DCIS发病率不断上升,本研究旨在确定采用保乳手术和根治性乳腺放疗治疗不可触及的、乳腺钼靶检测到的乳腺导管内癌的治疗结果。
对110例单侧、不可触及的、乳腺钼靶检测到的乳腺导管内癌患者进行了分析,这些患者在欧洲和美国的10家机构接受了保乳手术和根治性乳腺放疗。所有患者均对原发性肿瘤进行了完整的大体切除,并进行了根治性的乳腺放疗。进行病理腋窝淋巴结分期时,淋巴结均为阴性(n = 29)。中位随访时间为9.3年。
10年精算总生存率为93%,10年精算病因特异性生存率为96%。10年精算无远处转移率为96%。治疗的乳腺中有15例局部复发。局部失败的精算率在5年时为7%,10年时为14%。局部复发的组织学类型为导管内癌9例,浸润性导管癌(伴有或不伴有相关导管内癌)6例。局部复发的中位时间为5.0年(平均5.4年;范围2.1 - 15.2年)。在挽救治疗后的中位随访时间为4.4年时,15例局部复发患者中有14例在最后一次随访检查时存活且无疾病证据。肿瘤切除的最终病理切缘阴性时,局部复发的粗发病率为7%(3/42),切缘接近或阳性时为29%(5/17),切缘未知时为14%(7/51)。基于原发性肿瘤的病理特征,局部复发率没有差异。
本研究结果表明,采用保乳手术和根治性乳腺放疗治疗不可触及的、乳腺钼靶检测到的乳腺DCIS后10年,总生存率、病因特异性生存率和无远处转移率均较高。治疗的乳腺内的局部复发被早期检测到,并通过挽救性治疗治愈。这些结果支持采用保乳手术和根治性乳腺放疗对不可触及的、乳腺钼靶检测到的乳腺DCIS进行初始治疗。患者选择的改善有可能降低局部复发的风险。